Cargando…
In Global Health Research, Is It Legitimate To Stop Clinical Trials Early on Account of Their Opportunity Costs?
After the failure of three large clinical trials of vaginal microbicides, a Nature editorial stated that the microbicide field “requires a mechanism to help it make rational choices about the best candidates to move through trials” [1]. In this month's debate, James Lavery and colleagues propos...
Autores principales: | Lavery, James V., Singer, Peter A., Ridzon, Renee, Singh, Jerome A., Slutsky, Arthur S., Anisko, Joseph J., Buchanan, David |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686164/ https://www.ncbi.nlm.nih.gov/pubmed/19513106 http://dx.doi.org/10.1371/journal.pmed.1000071 |
Ejemplares similares
-
Which New Approaches to Tackling Neglected Tropical Diseases Show Promise?
por: Spiegel, Jerry M., et al.
Publicado: (2010) -
Is It Ethical to Use Enhancement Technologies to Make Us Better than Well?
por: Caplan, Arthur, et al.
Publicado: (2004) -
Is the “3 by 5” Initiative the Best Approach to Tackling the HIV Pandemic?
por: Kim, Jim Yong, et al.
Publicado: (2004) -
What Should Be Done To Tackle Ghostwriting in the Medical Literature?
por: Gøtzsche, Peter C, et al.
Publicado: (2009) -
What Are the Public Health Effects of Direct-to-Consumer Drug Advertising?
por: Almasi, Elizabeth A, et al.
Publicado: (2006)